SynthesisFrontiers in neurology2021
Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.
Synthesis in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860633 (Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod: A Single Arm, Open Label Prospective Cohort Study
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Pooled it
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case.Journal of clinical medicine · 2026Review
- Article
- Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation.CNS neuroscience & therapeutics · 2026Article
- Comprehensive review on myasthenia gravis: patho-physiology, diagnosis, management strategies.Wiener medizinische Wochenschrift (1946) · 2026Review
- Association Between Specialist Distribution and Regional Variation in Plasmapheresis Use in Japan: A Population-Level Cross-Sectional Study.Journal of clinical apheresis · 2026Article
- Double-Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity-Stratified Benefits in a Prospective Observational Multicenter Study.CNS neuroscience & therapeutics · 2026Observational
- Complications of Therapeutic Plasma Exchange in Pediatric Neuroimmune Disorders.Children (Basel, Switzerland) · 2025Article
- Clinical and economic outcomes of myasthenia gravis and myasthenic crisis when treated with PLEX and IVIG.Frontiers in neurology · 2025Article
- Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of pathomechanisms.Frontiers in immunology · 2025Article
- Targeted Treatments for Myasthenia Gravis in Children and Adolescents.Paediatric drugs · 2024Review
- Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment.European journal of neurology · 2024Review
- Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.Nature reviews. Neurology · 2024Review
- Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod.Frontiers in neurology · 2024Article
- Therapeutic Plasma Exchange in AChR-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response.Journal of inflammation research · 2024Article
- Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial.BMJ neurology open · 2024Article
- Successful Emergency Management of a Dog with Ventilator-Dependent Acquired Myasthenia Gravis with Immunoadsorption.Animals : an open access journal from MDPI · 2023Article
- Plasma Exchange versus Intravenous Immunoglobulin in Worsening Myasthenia Gravis: A Systematic Review and Meta-Analysis with Special Attention to Faster Relapse Control.Biomedicines · 2023Review
- Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.Aging and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.